Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(PALI)$3.50 /P2 data overdue, trial results could hit the wire any day now if positive the dirt cheap low float stock could explode like a bomb .
A sister Phase 2 study that is virtually identical in design to PROFILE, was recently completed with co-development partner Newsoara (Shanghai, China). It included more than 120 patients, has the same primary and secondary endpoints as PROFILE, and preliminary top-line data are expected to be announced by the end of Q2 2021.
(PALI)MC $25m /P2 data overdue, trial results could hit the wire any day now if positive the dirt cheap low float stock could explode like a bomb .
A sister Phase 2 study that is virtually identical in design to PROFILE, was recently completed with co-development partner Newsoara (Shanghai, China). It included more than 120 patients, has the same primary and secondary endpoints as PROFILE, and preliminary top-line data are expected to be announced by the end of Q2 2021.
(OCUP)$4.55 about to Breakout ...important Phase 3 readout within weeks
PALI next VRPX ..low float biotech with IMMINENT phase 2 data readout .
(PALI)$3.60/LOW FLOAT /P2 data overdue, trial results could hit the wire any day now if positive the dirt cheap low float stock could explode like a bomb .
A sister Phase 2 study that is virtually identical in design to PROFILE, was recently completed with co-development partner Newsoara (Shanghai, China). It included more than 120 patients, has the same primary and secondary endpoints as PROFILE, and preliminary top-line data are expected to be announced by the end of Q2 2021.
(ERYP)$4.80-2x Cancer Drugs nearing APPROVAL
(ERYP) $4.80 --Potential BLA filings for 2 Cancer Drugs with big market potential within 6 months with potential FDA approval by mid next year for BOTH indications and more clinical data readout expected during second half of this year =this under radar stock could be a $50+ stock within 12-18 months .
(PALI)$3.93 /P2 data overdue, trial results could hit the wire any day now if positive the dirt cheap low float stock could explode like a bomb .
A sister Phase 2 study that is virtually identical in design to PROFILE, was recently completed with co-development partner Newsoara (Shanghai, China). It included more than 120 patients, has the same primary and secondary endpoints as PROFILE, and preliminary top-line data are expected to be announced by the end of Q2 2021.
OCUP movinggg again ..Phase 3 readout coming within 8 weeks
(SCPH)$6.50 runningggggggggg ..BLOCKBUSTER Phase 3 drug with IMMINENT data readout expected THIS month ..Has potential to be the next 10 bagger
“At the same time, we recently completed enrollment in our FREEDOM-HF study and anticipate topline data in July. The results, if positive, can potentially demonstrate significant cost savings from treating congestion in patients with heart failure with FUROSCIX outside of the hospital setting. We are looking forward to better understanding the potential pharmacoeconomic impact of FUROSCIX within this patient population, and the promise of reducing the burden of heart failure.”
NRBO after VRPX ...NRBO with imminent covid data readout expected THIS month ..very underpriced low floater with big upside
(NRBO) covid data THIS week = $$$$$
VRPX runningggggg
SCPH about to breakout guys ,,very hot and underpriced biotech
(VRPX)$4-float 2m-try to BReakout
(SCPH)next MEGA Biotech under radar
$5.60 -They expect to resubmit NDA for their potential Blockbuster in Q3 and to release important clinical data also in Q3 ..this low float stock has 10 bagger upside ..
FREEDOM clinical study on track for topline results in Q3 2021
ScPharmaceuticals Sees US Application Submission For Furoscix In Q3
https://finance.yahoo.com/news/scpharmaceuticals-sees-us-application-submission-160327548.html
New presentation
https://scpharmaceuticalsinc.gcs-web.com/static-files/9759ffa3-4af3-4df5-89cb-a48a521113ee
(SCPH)next MEGA Biotech under radar
$5.60 -They expect to resubmit NDA for their potential Blockbuster in Q3 and to release important clinical data also in Q3 ..this low float stock has 10 bagger upside ..
FREEDOM clinical study on track for topline results in Q3 2021
ScPharmaceuticals Sees US Application Submission For Furoscix In Q3
https://finance.yahoo.com/news/scpharmaceuticals-sees-us-application-submission-160327548.html
New presentation
https://scpharmaceuticalsinc.gcs-web.com/static-files/9759ffa3-4af3-4df5-89cb-a48a521113ee
OCUP= RALLYYYYYYYYYYYYYYYYYYY
VRPX =float 2 m-start moving ..
(VRPX)$3.90-float 2 m--could start running again
(VRPX)4.20 /Float 2 m-another BREAKOUT imminent
(OCUP)4.90-MEGA readout THIS month ..earlier this year the stock jumped from $6 to $16 in pre market on positive phase 3 readout ..Market cap only 77 million its dirt cheap biotech .GL
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
https://seekingalpha.com/article/4428155-ocuphires-low-market-cap-masks-significant-pipeline-potential
(OCUP)4.90-MEGA readout THIS month ..earlier this year the stock jumped from $6 to $16 in pre market on positive phase 3 readout ..Market cap only 77 million its dirt cheap biotech .GL
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
https://seekingalpha.com/article/4428155-ocuphires-low-market-cap-masks-significant-pipeline-potential
(VRPX)MC 20 m-float 2m-Breakout on the way ..very cheap biotech gem with big product pipeline
(VRPX) up 11%--Float 2 m --Market cap 20 million ..very attractive and underpriced biotech
SNPX explodingggggg...cheapest ALZHEIMER bomb
(SNPX)$8-float 1m-BREAKOUT imminent
Cheapest Alzheimer gem out there market cap only 28 million while competitors like SAVA trading at $2.8 BILLION valuation
(APLIF)$0.69-Covid Phase 3 data next month ..this unknown stock could be a monster opp with potential 10 bagger upside and more ..check out their presentation below for more infos guys
Presentation
https://7343a5f0-1b48-4477-8577-969ff9b4ed06.filesusr.com/ugd/3d295b_1f46930ba5c145d0a6caacdccc93437d.pdf
SNPX $8-float 1m about to EXPLODEEE ,its the cheapest Alzheimer gem on markets
(SNPX) MCap $27 m--float 1 m- MEGA Blockbuster in Phase 2b with results around the corner ($10+ BILLION market) / NEW Nasdaq listed ..could move like ORPH or ANVS did
https://apis.mail.yahoo.com/ws/v3/mailboxes/@.id==VjN-FCRyES4NeKxg1WB6KzdHsahvmOAHyCDMX1UZcxYuolHvefazfj9WLG9hCxP1XVW0EgGu3Y1YiD9202GxiJJSNg/messages/@.id==AAfjxrx-QrQ-YMM5VgYiUKqqaFU/content/parts/@.id==2/thumbnail?appid=YMailNorrin
(SNPX) 1m float EXPLODINGGGGGGG its the cheapest alzheimer gem you can get
SNPX next ORPHA only 1 m float ..low float bomb about to explodeee
(SNPX) MCap $25 m--Float 1 m--MEGA Alzheimer Phase 2b drug with imminent readout /NEW nasdaq stock ..
SNPX next ORPHA only 1 m float ..low float bomb about to explodeee
(SNPX) MCap $25 m--Float 1 m--MEGA Alzheimer Phase 2b drug with imminent readout /NEW nasdaq stock ..
SNPX next ORPH ...market cap laughabe 25 million and only 3.5 million outstanding shares its the cheapest Alheizmer stock in the entire market with Phase 2b readout around the corner .